Supporting Information

Trifluoromethylthiolation-Based Bifunctionalization of Diazocarbonyl Compounds by Rhodium Catalysis

Marvin Lübcke,^{ab} Weiming Yuan^a and Kálmán J. Szabó*^{ab}

^a Department of Organic Chemistry, Stockholm University Arrhenius Laboratory, SE-106 91 Stockholm, Sweden

^b Stockholm Brain Institute, Karolinska Institutet, SE-171 77 Stockholm, Sweden

E-mail: kalman.j.szabo@su.se

Contents:

Page S2	General information
Page S3	Synthesis and characterization
Page S14	Attempted cleavage of epoxides
Page S15	Mechanistical aspects: competitive fluorination vs. trifluoromethylthiolation
	and proposed catalytic cycle
Page S17	¹ H NMR, ¹³ C NMR and ¹⁹ F NMR spectra
Page S95	References

General Information

Diazo compounds 2 were prepared according to literature procedures.¹⁻³ Trifluoromethylthiolating reagent 1 was synthesized according to a procedure by Shen and coworkers.⁴ Reagents were used as obtained from commercial suppliers without further purification. Dry CDCl₃ was used as obtained from a commercial supplier (Sigma-Aldrich). Dry CH₂Cl₂ was obtained from a solvent drying system (VAC Solvent Purifier from Vacuum Atmospheres). Flash chromatography was carried out on 60 Å (35-70 µm) silica gel (Davisil by Grace Discovery Sciences)) using petroleum ether / Et₂O or petroleum ether / CH₂Cl₂ mixtures as eluent. Analytical TLC was carried out on aluminum-backed plates (1.5 Å, ~ 5 cm) pre-coated (0.25 mm) with silica gel (Merck, Silica Gel 60 F254). Compounds were visualized by exposure to UV light or by dipping the plates in a solution of 0.75% KMnO₄ (w/v) in a aqueous solution of K₂CO₃ 0.36 M. Melting points were recorded in a metal block and are uncorrected. ¹H NMR spectra were recorded at 400 MHz; ¹³C NMR spectra were recorded at 100 MHz, ¹⁹F NMR spectra were recorded at 377 MHz with a Bruker Advance spectrometer. ¹H and ¹³C NMR chemical shifts (δ) are reported in ppm from tetramethylsilane, using the residual solvent resonance (CHCl₃: δ_H 7.26 and CDCl₃: δ_C 77.0) as an internal reference. Coupling constants (J) are given in Hz. High-resolution mass spectra (HRMS) were recorded with a Bruker microTOF ESI-TOF mass spectrometer.

Experimental procedures and spctroscopic data

General procedure A for the multicomponent reaction of diazo compounds 2 with alcohols 3 and trifluoromethylthio reagent 1.

$$\begin{array}{c} O \\ R^{1} \\ \hline \\ \mathbf{2} \\ \mathbf{2} \\ \mathbf{1} \\ \mathbf{2} \\ \mathbf{1} \\ \mathbf{3} \\ \mathbf{3} \\ \mathbf{1} \\ \mathbf{3} \\ \mathbf{1} \\ \mathbf{3} \\ \mathbf{1} \\ \mathbf{1} \\ \mathbf{3} \\ \mathbf{1} \\$$

(PhSO₂)₂NSCF₃ (1) (40 mg, 0.1 mmol, 1.0 equiv.), Rh₂(OAc)₄ (4) (0.5 mg, 0.001 mmol, 0.01 equiv.) and anhydrous NaOAc (16 mg, 0.2 mmol, 2.0 equiv.) were placed to a vial under ambient conditions. Then, diazo compound 2 (0.12 mmol, 1.2 equiv.) and the corresponding alcohol 3 (0.4 mmol, 4.0 equiv.) in 1.5 mL of dry CDCl₃ were added under Ar. The reaction mixture was stirred for 30 minutes in the sealed vial, then the reaction mixture was purified by silica gel chromatography to obtain products 5.

General procedure B for the multicomponent reaction of diazo compounds 2 with ethers 6, 7c and reagent 1.

 $(PhSO_2)_2NSCF_3$ (1) (40 mg, 0.1 mmol, 1.0 equiv.) and $Rh_2(OAc)_4$ (4) (0.5 mg, 0.001 mmol, 0.01 equiv.) were placed to a vial under ambient conditions. Then, diazo compound 2 (0.12 mmol, 1.2 equiv.) in 1 mL of the appropriate ether 6 or 7c were added under Ar. The reaction mixture was stirred for 2 h in the sealed vial, then the reaction mixture was purified by silica gel chromatography.


General procedure C for the multicomponent reaction of diazo compounds 2 with THF 7a-b and reagent 1.

$$\begin{array}{c} O \\ R^{1} \\ \hline \end{array} \\ R^{2} \\ \mathbf{2} \\ \mathbf{1} \\ \mathbf{2} \\ \mathbf{1} \\ \mathbf{1}$$

(PhSO₂)₂NSCF₃ (1) (40 mg, 0.1 mmol, 1.0 equiv.) and Rh₂(OAc)₄ (4) (0.5 mg, 0.001 mmol,

0.01 equiv.) were placed to a vial under ambient conditions. Then, diazo compound **2** (0.12 mmol, 1.2 equiv.) and THF **7** (0.6 mmol, 6 equiv.) in 1 mL of dry CH_2Cl_2 were added under Ar. The reaction mixture was stirred for 2 h in the sealed vial, then the reaction mixture was purified by silica gel chromatography.

2-(benzyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5a)




Title compound **5a** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5a** as a colorless oil (23 mg, 71%). ¹H NMR (400 MHz,

CDCl₃): $\delta = 8.07-8.03$ (m, 2H), 7.67-7.62 (m, 1H), 7.53-7.47 (m, 2H), 7.34-7.29 (m, 3H), 7.26-7.22 (m, 2H), 6.59 (s, 1H), 4.86 (d, J = 11.0 Hz, 1H), 4.56 (d, J = 11.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.4$, 135.7, 134.8, 133.1, 130.3 (q, J(C,F) = 308.2 Hz), 129.6, 129.1, 128.7, 128.6, 128.5, 87.1 (q, J(C,F) = 1.6 Hz), 69.2; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.47$; HRMS (ESI): m/z calcd. for C₁₆H₁₃O₂F₃S+Na⁺: 349.0481 [*M*+Na]⁺; found: 349.0463.

2-(benzyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5a) at 1.0 mmol scale

The above preparation of **5a** was repeated at 1.0 mmol scale: $(PhSO_2)_2NSCF_3$ (**1**) (413 mg, 1.0 mmol, 1.0 equiv.), $Rh_2(OAc)_4$ (**4**) (4.9 mg, 0.01 mmol, 0.01 equiv.) and anhydrous NaOAc (169 mg, 2.0 mmol, 2.0 equiv.) were placed in a 25 mL Schlenk tube under ambient conditions. Then, diazo compound **2a** (189 mg, 1.2 mmol, 1.2 equiv.) and benzyl alcohol **3a** (433 mg, 4.0 mmol, 4.0 equiv.) dissolved together in 15 mL dry CDCl₃ were added under Ar. This reaction mixture was stirred for 30 minutes at 25 °C, then the solvent was removed under reduced pressure. The crude mixture was purified by silica gel chromatography (SiO₂; petroleum ether / Et₂O, 16:1) to obtain product **5a** (229 mg, 67% yield).

2-(naphthalen-2-ylmethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5b)




Title compound **5b** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et_2O , 16:1) affording **5b** as a colorless oil (25 mg, 67%). ¹H NMR

(400 MHz, CDCl₃): $\delta = 8.07-8.03$ (m, 2H), 7.83-7.76 (m, 3H), 7.72-7.69 (m, 1H), 7.66-7.61 (m, 1H), 7.51-7.45 (m, 4H), 7.34 (dd, J = 8.4 Hz, 1.7 Hz, 1H), 6.63 (s, 1H), 5.02 (d, J = 11.1 Hz, 1H), 4.74 (d, J = 11.1 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.4$, 134.7, 133.3, 133.3, 133.1, 130.4 (q, J(C,F) = 308.2 Hz), 129.6, 129.1, 128.6, 128.1, 127.8, 127.7, 126.5, 126.4, 125.8, 87.0 (q, J(C,F) = 1.6 Hz), 69.3; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.39$; HRMS

(ESI): m/z calcd. for C₂₀H₁₅O₂F₃S+Na⁺: 399.0637 [*M*+Na]⁺; found: 399.0653.


2-((2-bromobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5c)



Title compound **5c** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5c** as a colorless oil (20 mg, 50%). ¹H NMR (400 MHz,

CDCl₃): $\delta = 8.10-8.06$ (m, 2H), 7.67-7.61 (m, 1H), 7.54-7.47 (m, 3H), 7.40-7.36 (m, 1H), 7.31-7.25 (m, 1H), 7.18-7.13 (m, 1H), 6.62 (s, 1H), 4.89 (d, J = 11.8 Hz, 1H), 4.72 (d, J = 11.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.1$, 135.3, 134.8, 133.0, 132.8, 130.3 (q, J(C,F) = 308.3 Hz), 130.1, 129.9, 129.7, 129.1, 128.7, 127.7, 87.4 (q, J(C,F) = 1.6 Hz), 68.8; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.52$; HRMS (ESI): m/z calcd. for C₁₆H₁₂O₂F₃S⁷⁹Br+Na⁺: 426.9586 [M+Na]⁺; found: 426.9573.


2-((4-nitrobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5d)



Title compound **5d** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5d** as a yellowish oil (13 mg, 33%). ¹H NMR

(400 MHz, CDCl₃): $\delta = 8.19-8.14$ (m, 2H), 8.09-8.04 (m, 2H), 7.70-7.65 (m, 1H), 7.56-7.50 (m, 2H), 7.44-7.39 (m, 2H), 6.73 (s, 1H), 4.97 (d, J = 12.2 Hz, 1H), 4.63 (d, J = 12.2 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.1$, 147.9, 143.2, 135.1, 132.8, 130.2 (q, J(C,F) = 308.3 Hz), 129.5, 129.3, 128.4, 123.8, 87.1 (q, J(C,F) = 1.5 Hz), 67.4; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.66$; HRMS (ESI): m/z calcd. for C₁₆H₁₂O₄NF₃S+Na⁺: 394.0331 [*M*+Na]⁺; found: 394.0324.


2-(benzo[d][1,3]dioxol-5-ylmethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5e)



Title compound **5e** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et_2O , 16:1) affording **5e** as a colorless oil (24 mg, 58%). ¹H NMR

(400 MHz, CDCl₃): $\delta = 8.07-8.01$ (m, 2H), 7.68-7.62 (m, 1H), 7.54-7.47 (m, 2H), 6.75-6.67 (m, 3H), 6.56 (s, 1H), 5.95-5.92 (m, 2H), 4.75 (d, J = 10.8 Hz, 1H), 4.46 (d, J = 10.8 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.5$, 148.0, 147.9, 134.7, 133.1, 130.3 (q, J(C,F) = 308.2 Hz), 129.6, 129.3, 129.1, 122.6, 109.2, 108.3, 101.3, 86.8 (q, J(C,F) = 1.5 Hz), 69.1; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.45$; HRMS (ESI): m/z calcd. for C₁₇H₁₃O₄F₃S+Na⁺: 393.0379 [M+Na]⁺; found: 393.0387.


2-(hexyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5f)



Title compound **5f** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5f** as a colorless oil (22 mg, 68%). ¹H NMR

(400 MHz, CDCl₃): $\delta = 8.10-8.06$ (m, 2H), 7.67-7.62 (m, 1H), 7.54-7.48 (m, 2H), 6.50 (s, 1H), 3.76 (dt, J = 9.0 Hz, 6.4 Hz, 1H), 3.49 (dt, J = 9.0 Hz, 6.4 Hz, 1H), 1.61-1.53 (m, 2H), 1.34-1.15 (m, 6H), 0.84 (t, J = 6.9 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.7$, 134.7, 133.1, 130.5 (q, J(C,F) = 307.9 Hz), 129.6, 128.9, 88.2 (q, J(C,F) = 1.5 Hz), 67.4, 31.5, 29.2, 25.6, 22.6, 14.1; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.68$; HRMS (ESI): m/z calcd. for C₁₅H₁₉O₂F₃S+Na⁺: 343.0950 [*M*+Na]⁺; found: 343.0955.


2-(cycloheptyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5g)



Title compound **5g** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5g** as a colorless oil (20 mg, 54%). ¹H NMR (400 MHz, CDCl₃):

δ = 8.09-8.04 (m, 2H), 7.65-7.59 (m, 1H), 7.53-7.46 (m, 2H), 6.13 (s, 1H), 4.03 (tt, *J* = 8.1 Hz, 4.4 Hz, 1H), 1.94-1.84 (m, 2H), 1.75-1.57 (m, 4H), 1.56-1.47 (m, 4H), 1.42-1.32 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.2, 134.1, 133.2, 130.3 (q, *J*(C,F) = 308.3 Hz), 129.8, 128.8, 85.8 (q, *J*(C,F) = 1.4 Hz), 80.1, 34.7, 33.2, 28.4, 28.4, 22.9, 22.6; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.51; HRMS (ESI): m/z calcd. for C₁₆H₁₉O₂F₃S+Na⁺: 355.0950 [*M*+Na]⁺; found: 355.0953.

2-(((1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5h)




Title compound **5h** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5h** as a colorless oil (17 mg, 46%, dr = 1:1.4). As a mixture of

two diastereoisomers: ¹H NMR (400 MHz, CDCl₃): δ = 8.08-8.00 (m, 2H), 7.65-7.59 (m, 1H), 7.52-7.46 (m, 2H), 6.06 & 6.00 (s, 1H), 3.71 & 3.51 (td, *J* = 10.6 Hz, 4.3 Hz, 1H), 2.31-1.95 (m, 2H), 1.73-1.60 (m, 2H), 1.45-1.27 (m, 2H), 1.15-0.97 (m, 1H), 0.96-0.90 (m, 5H), 0.88-0.80 (m, 4H), 0.64-0.60 (m, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 190.5 (major) & 190.9 (minor), 134.2 (major) & 134.3 (minor), 132.9 (major) & 133.0 (minor), 130.2 (q, *J*(C,F) = 308.3 Hz, major), 130.1 (q, *J*(C,F) = 308.7 Hz, minor), 129.8 (major) & 129.8 (minor), 128.9 (minor), 84.7 (q, *J*(C,F) = 1.3 Hz, major) & 86.2 (q, *J*(C,F) = 1.5 Hz, minor),

78.8 (major) & 82.0 (minor), 47.9 (major) & 48.7 (minor), 39.3 (major) & 41.3 (minor), 34.3 (major) & 34.2 (minor), 31.6 (major) & 31.8 (minor), 25.5 (major) & 25.3 (minor), 23.0 (major) & 23.0 (minor), 22.3 (major) & 22.3 (minor), 21.2 (major) & 21.2 (minor), 15.9 (major) & 15.8 (minor); ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.27 (major), -38.62 (minor); HRMS (ESI): m/z calcd. for C₁₉H₂₅O₂F₃S+Na⁺: 397.1420 [*M*+Na]⁺; found: 397.1427.


2-((3-methylbut-2-en-1-yl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5i)



Title compound **5i** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5i** as a colorless oil (21 mg, 66%). ¹H NMR (400 MHz,

CDCl₃): δ = 8.09-8.05 (m, 2H), 7.66-7.61 (m, 1H), 7.53-7.47 (m, 2H), 6.50 (s, 1H), 5.25 (tdt, *J* = 7.2 Hz, 2.9 Hz, 1.5 Hz, 1H), 4.30 (dd, *J* = 11.2 Hz, 7.2 Hz, 1H), 4.08 (dd, *J* = 11.2 Hz, 7.2 Hz, 1H), 1.70 (s, 3H), 1.58 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.8, 140.5, 134.6, 133.2, 130.4 (q, *J*(C,F) = 308.0 Hz), 129.6, 129.0, 118.8, 87.2 (q, *J*(C,F) = 1.6 Hz), 63.8, 25.9, 18.1; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.62; HRMS (ESI): m/z calcd. for C₁₄H₁₅O₂F₃S+Na⁺: 327.0637 [*M*+Na]⁺; found: 327.0650.


2-((4-bromobenzyl)oxy)-1-(p-tolyl)-2-((trifluoromethyl)thio)ethan-1-one (5j)



Title compound **5j** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 20:1) affording **5j** as a colorless oil (21 mg, 49%). ¹H NMR

(400 MHz, CDCl₃): δ = 7.97-7.92 (m, 2H), 7.45-7.41 (m, 2H), 7.32-7.28 (m, 2H), 7.13-7.09 (m, 2H), 6.62 (s, 1H), 4.80 (d, *J* = 11.2 Hz, 1H), 4.46 (d, *J* = 11.2 Hz, 1H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 190.9, 146.2, 134.9, 131.8, 130.5, 130.4 (q, *J*(C,F) = 308.2 Hz), 130.0, 129.9, 129.7, 122.5, 87.2 (q, *J*(C,F) = 1.5 Hz), 68.0, 22.0; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.60; HRMS (ESI): m/z calcd. for C₁₇H₁₄O₂F₃S⁷⁹Br+Na⁺: 440.9748 [*M*+Na]⁺; found: 440.9749.

2-(benzyloxy)-1-cyclopentyl-2-((trifluoromethyl)thio)ethan-1-one (5k)




Title compound **5k** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5k** as a colorless oil (21 mg, 63%). ¹H NMR (400 MHz,

CDCl₃): δ = 7.42-7.32 (m, 5H), 5.49 (s, 1H), 4.86 (d, *J* = 11.6 Hz, 1H), 4.70 (d, *J* = 11.8 Hz, 1H), 1.93-1.52 (m, 8H); ¹³C NMR (100 MHz, CDCl₃): δ = 205.0, 135.6, 130.1 (q, *J*(C,F) =

308.4 Hz), 128.8, 128.7, 128.4, 86.6 (q, J(C,F) = 1.2 Hz), 70.6, 47.1, 30.1, 29.7, 26.3, 26.2; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -37.56$; HRMS (ESI): m/z calcd. for C₁₅H₁₇O₂F₃S+Na⁺: 341.0799 [*M*+Na]⁺; found: 341.0793.

1-(benzyloxy)-1-((trifluoromethyl)thio)undecan-2-one (5l)




CDCl₃): δ = 7.41-7.32 (m, 5H), 5.35 (s, 1H), 4.88 (d, *J* = 11.6 Hz, 1H), 4.67 (d, *J* = 11.8 Hz, 1H), 2.71-2.56 (m, 2H), 1.64-1.56 (m, 2H), 1.32-1.21 (m, 12H), 0.88 (t, *J* = 6.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 202.5, 135.5, 130.0 (q, *J*(C,F) = 308.6 Hz), 128.9, 128.7, 128.5, 86.8 (q, *J*(C,F) = 1.2 Hz), 70.7, 38.4, 32.0, 29.5, 29.5, 29.4, 29.1, 23.5, 22.8, 14.2; ¹⁹F NMR (377 MHz, CDCl₃): δ = -37.35; HRMS (ESI): m/z calcd. for C₁₉H₂₇O₂F₃S+Na⁺: 399.1582 [*M*+Na]⁺; found: 399.1587.

1-(hexyloxy)-1-((trifluoromethyl)thio)undecan-2-one (5m)

Title compound **5m** was prepared according to general procedure C_8H_{17} , C_8

¹H NMR (400 MHz, CDCl₃): $\delta = 5.32$ (s, 1H), 3.79 (dt, J = 9.2 Hz, 6.6 Hz, 1H), 3.54 (dt, J = 9.2 Hz, 6.6 Hz, 1H), 2.71-2.55 (m, 2H), 1.69-1.57 (m, 4H), 1.40-1.21 (m, 18H), 0.92-0.85 (m, 6H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 202.9$, 130.2 (q, J(C,F) = 308.1 Hz), 88.4 (q, J(C,F) = 1.1 Hz), 69.6, 38.2, 32.0, 31.6, 29.5, 29.5, 29.4, 29.2, 29.1, 25.8, 23.5, 22.8, 22.7, 14.2, 14.1; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -37.64$; HRMS (ESI): m/z calcd. for C₁₈H₃₃O₂F₃S+Na⁺: 393.2051 [*M*+Na]⁺; found: 393.2057.

2-(benzyloxy)-2-((trifluoromethyl)thio)-2,3-dihydro-1*H*-inden-1-one (5n)



Title compound **5n** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5n** as a colorless oil (29 mg, 75%). ¹H NMR (400 MHz,

CDCl₃): δ = 7.86-7.82 (m, 1H), 7.71-7.66 (m, 1H), 7.48-7.41 (m, 2H), 7.34-7.26 (m, 5H), 5.03 (d, *J* = 11.3 Hz, 1H), 4.84 (d, *J* = 11.3 Hz, 1H), 3.88 (d, *J* = 17.4 Hz, 1H), 3.67 (d, *J* = 17.4 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 195.5, 149.6, 136.7, 136.7, 132.3, 130.1 (q, *J*(C,F) = 309.8 Hz), 128.7, 128.5, 128.2, 128.1, 126.5, 125.9, 93.9, 68.0, 43.6 (q, *J*(C,F) = 1.6 Hz);

¹⁹F NMR (377 MHz, CDCl₃): δ = -35.33; HRMS (ESI): m/z calcd. for C₁₇H₁₃O₂F₃S+Na⁺: 361.0486 [*M*+Na]⁺; found: 361.0470.

ethyl 2-(benzyloxy)-2-((trifluoromethyl)thio)acetate (50)

Title compound **50** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **50** as a colorless oil (8.0 mg, 27%). ¹H NMR (400 MHz, CDCl₃): $\delta = 7.39-7.32$ (m, 5H), 5.49 (s, 1H), 4.85 (d, J = 11.6 Hz, 1H), 4.74 (d, J = 11.6 Hz, 1H), 4.28 (qd, J = 7.1 Hz, 1.5 Hz, 2H), 1.31 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 166.5$, 135.5, 129.9 (q, J(C,F) = 308.5 Hz), 128.8, 128.7, 128.6, 80.9 (q, J(C,F) = 2.0 Hz), 70.5, 62.8, 14.1; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.32$; HRMS (ESI): m/z calcd. for C₁₂H₁₃O₃F₃S+Na⁺: 317.0435 [*M*+Na]⁺; found: 317.0429.

methyl 2-(benzyloxy)-2-phenyl-2-((trifluoromethyl)thio)acetate (5p)


Title compound **5p** was prepared according to general procedure A and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5p** as a white solid (8.0 mg, 20%). ¹H NMR (400 MHz, CDCl₃): δ = 7.72-7.68 (m, 2H), 7.48-7.44 (m, 2H), 7.43-7.33 (m, 6H), 5.05 (d, *J* = 10.7 Hz, 1H), 4.56 (d, *J* = 10.7 Hz, 1H), 3.75 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 168.9 (q, *J*(C,F) = 1.8 Hz), 138.0, 136.4, 129.4 (q, *J*(C,F) = 309.4 Hz), 129.3, 128.6, 128.6, 128.2, 128.2, 126.4, 97.0 (q, *J*(C,F) = 1.4 Hz), 68.8, 53.9; ¹⁹F NMR (377 MHz, CDCl₃): δ = -37.47; HRMS (ESI): m/z calcd. for C₁₇H₁₅O₃F₃S+Na⁺: 379.0592 [*M*+Na]⁺; found: 379.0600; Mp: 78.5-79.5 °C.

2-methoxy-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5q)

Title compound **5q** was prepared according to general procedure B from dimethoxymethane and trimethyl orthoformate and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5q** as a colorless

oil (11 mg, 41% from dimethoxymethane; 15 mg, 55% from trimethyl orthoformate). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.08-8.03$ (m, 2H), 7.68-7.62 (m, 1H), 7.55-7.48 (m, 2H), 6.47 (s, 1H), 3.48 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.4$, 134.8, 133.0, 130.3 (q, *J*(C,F) = 308.0 Hz), 129.6, 129.1, 88.8 (q, *J*(C,F) = 1.6 Hz), 54.6; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.70$; HRMS (ESI): m/z calcd. for C₁₀H₉O₂F₃S+Na⁺: 273.0168 [*M*+Na]⁺; found: 273.0175.


1-(4-bromophenyl)-2-methoxy-2-((trifluoromethyl)thio)ethan-1-one (5r)



Title compound **5r** was prepared according to general procedure B and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 16:1) affording **5r** as a colorless oil (12 mg, 34%). ¹H NMR (400 MHz, CDCl₃):

δ = 7.95-7.90 (m, 2H), 7.69-7.63 (m, 2H), 6.36 (s, 1H), 3.48 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 190.5, 132.5, 131.7, 131.0, 130.3, 130.2 (q, *J*(C,F) = 308.1 Hz), 88.8 (q, *J*(C,F) = 1.5 Hz), 54.8; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.65; HRMS (ESI): m/z calcd. for C₁₀H₈O₂F₃S⁷⁹Br+Na⁺: 350.9278 [*M*+Na]⁺; found: 350.9279.


2-(2-(2-methoxyethoxy)ethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5s)



Title compound **5s** was prepared according to general procedure B and purified by column chromatography (SiO₂; petroleum ether / CH₂Cl₂, 1:1) affording **5s** as a colorless oil (24 mg, 72%).

¹H NMR (400 MHz, CDCl₃): δ = 8.10-8.04 (m, 2H), 7.66-7.60 (m, 1H), 7.53-7.46 (m, 2H), 6.61 (s, 1H), 4.00-3.92 (m, 1H), 3.79-3.72 (m, 1H), 3.68-3.64 (m, 2H), 3.58-3.48 (m, 2H), 3.44-3.40 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.3, 134.6, 133.2, 130.3 (q, *J*(C,F) = 308.2 Hz), 129.6, 129.0, 87.4 (q, *J*(C,F) = 1.5 Hz), 71.9, 70.6, 70.1, 66.9, 59.1; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.55; HRMS (ESI): m/z calcd. for C₁₄H₁₇O₄F₃S+Na⁺: 361.0692 [*M*+Na]⁺; found: 361.0702.


N-(4-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8a)



Title compound **8a** was prepared according to general procedure C and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 3:1) affording **8a** as a colorless oil (40

mg, 66%). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.08-8.03$ (m, 2H), 8.02-7.96 (m, 4H), 7.68-7.61 (m, 3H), 7.56-7.48 (m, 6H), 6.52 (s, 1H), 3.71 (dt, J = 9.0 Hz, 6.1 Hz, 1H), 3.69-3.63 (m, 2H), 3.42 (dt, J = 9.0 Hz, 6.1 Hz, 1H), 1.77-1.67 (m, 2H), 1.58-1.48 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.4$, 139.9, 134.9, 134.0, 132.8, 130.4 (q, J(C,F) = 308.0 Hz), 129.5, 129.2, 129.1, 128.2, 87.9 (q, J(C,F) = 1.3 Hz), 66.3, 49.1, 26.6, 26.2; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.54$; HRMS (ESI): m/z calcd. for C₂₅H₂₄O₆F₃S₃+Na⁺: 610.0610 [*M*+Na]⁺; found: 610.0619.


N-(4-(4-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)butoxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8b)



Title compound **8b** was prepared according to general procedure C using 60 equiv. of THF (**7a**) and purified by column chromatography (SiO₂;

petroleum ether / Et₂O, 3:1) affording **8b** as a colorless oil (27 mg, 42%). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.12$ -8.02 (m, 6H), 7.71-7.63 (m, 3H), 7.61-7.48 (m, 6H), 6.56 (s, 1H), 3.81 (dt, *J* = 9.0 Hz, 6.1 Hz, 1H), 3.76-3.69 (m, 2H), 3.52 (dt, *J* = 9.0 Hz, 6.1 Hz, 1H), 3.36-3.29 (m, 4H), 1.81-1.71 (m, 2H), 1.70-1.46 (m, 6H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 191.6$, 140.0, 134.8, 133.9, 132.9, 130.4 (q, *J*(C,F) = 307.9 Hz), 129.5, 129.2, 129.1, 128.2, 88.0 (q, *J*(C,F) = 1.6 Hz), 70.3, 70.1, 67.0, 49.5, 27.1, 26.8, 26.2, 26.1; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.55$; HRMS (ESI): m/z calcd. for C₂₉H₃₂O₇F₃S₃+Na⁺: 682.1185 [*M*+Na]⁺; found: 682.1187.


N-(4-((2-oxo-1-((trifluoromethyl)thio)undecyl)oxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8c)



Title compound **8c** was prepared according to general procedure C and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 3:1) affording **8c** as a colorless oil (34

mg, 50%). ¹H NMR (400 MHz, CDCl₃): $\delta = 8.05-8.00$ (m, 4H), 7.69-7.64 (m, 2H), 7.59-7.53 (m, 4H), 5.31 (s, 1H), 3.78-3.70 (m, 3H), 3.50 (dt, J = 9.2 Hz, 6.1 Hz, 1H), 2.69-2.52 (m, 2H), 1.85-1.77 (m, 2H), 1.66-1.56 (m, 4H), 1.33-1.21 (m, 12H), 0.87 (t, J = 6.8 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 202.3$, 140.0, 134.1, 130.1 (q, J(C,F) = 308.3 Hz), 129.3, 128.3, 88.1 (q, J(C,F) = 1.1 Hz), 68.6, 49.1, 38.3, 32.0, 29.5, 29.5, 29.4, 29.2, 26.7, 26.2, 23.4, 22.8, 14.2; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -37.61$; HRMS (ESI): m/z calcd. for C₂₈H₃₈O₆F₃S₃+Na⁺: 660.1711 [*M*+Na]⁺; found: 660.1724.

ethyl 2-(4-(*N*-(phenylsulfonyl)phenylsulfonamido)butoxy)-2-((trifluoromethyl)thio)acetate (8d)




Title compound **8d** was prepared according to general procedure C and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 3:1) affording **8d** as a colorless oil (21 mg, 38%). ¹H NMR

(400 MHz, CDCl₃): $\delta = 8.06-8.01$ (m, 4H), 7.68-7.63 (m, 2H), 7.59-7.53 (m, 4H), 5.46 (s, 1H), 4.29 (q, J = 7.6 Hz, 2H), 3.78-3.68 (m, 3H), 3.58 (dt, J = 9.1 Hz, 6.1 Hz, 1H), 1.87-1.76 (m, 2H), 1.67-1.57 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): $\delta = 166.4$, 140.1, 134.0, 129.9 (q, J(C,F) = 308.2 Hz), 129.2, 128.3, 82.2 (q, J(C,F) = 2.0 Hz), 68.4, 62.8, 49.2, 26.7, 26.2, 14.1; ¹⁹F NMR (377 MHz, CDCl₃): $\delta = -38.57$; HRMS (ESI): m/z calcd. for

C₂₁H₂₄NO₇F₃S+Na⁺: 578.0565 [*M*+Na]⁺; found: 578.0575.


N-(2-((2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)methyl)benzyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8e)



Title compound **8e** was prepared according to general procedure C using 60 equiv. of phthalane (**7b**) in 0.5 mL dry CH₂Cl₂. The title compound **8e** was purified by column chromatography (SiO₂; petroleum ether / Et₂O, 3:1) affording **8e** as a colorless oil (38 mg,

58%). ¹H NMR (400 MHz, CDCl₃): δ = 7.98-7.93 (m, 2H), 7.75-7.69 (m, 4H), 7.61-7.54 (m, 3H), 7.45-7.38 (m, 6H), 7.29-7.25 (m, 1H), 7.20-7.15 (m, 2H), 7.09-7.03 (m, 1H), 6.53 (s, 1H), 4.93 (d, *J* = 11.3 Hz, 1H), 4.92 (d, *J* = 16.4 Hz, 1H), 4.82 (d, *J* = 16.4 Hz, 1H), 4.75 (d, *J* = 11.3 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.1, 139.9, 134.7, 134.1, 133.8, 133.6, 133.0, 130.2 (q, *J*(C,F) = 308.4 Hz), 130.2, 129.6, 129.4, 129.1, 129.0, 128.9, 128.2, 128.0, 86.5 (q, *J*(C,F) = 1.5 Hz), 67.5, 48.8; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.34; HRMS (ESI): m/z calcd. for C₂₉H₂₄NO₆F₃S₃+Na⁺: 658.0616 [*M*+Na]⁺; found: 658.0621.

N-(2-(2-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)ethoxy)ethyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8f)



SCF3

Title compound **8f** was prepared according to general procedure B and purified by column chromatography (SiO₂; petroleum ether / Et₂O, 3:1) affording **8f** as a colorless oil (31

mg, 52%). ¹H NMR (400 MHz, CDCl₃): δ = 8.08-8.04 (m, 2H), 8.04-8.00 (m, 4H), 7.67-7.60 (m, 3H), 7.56-7.47 (m, 6H), 6.62 (s, 1H), 3.88-3.72 (m, 3H), 3.64-3.54 (m, 3H), 3.52-3.47 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 191.3, 139.7, 134.8, 134.0, 132.9, 130.3 (q, *J*(C,F) = 308.1 Hz), 129.6, 129.1, 129.1, 128.4, 87.6 (q, *J*(C,F) = 1.6 Hz), 69.8, 69.7, 66.3, 47.8; ¹⁹F NMR (377 MHz, CDCl₃): δ = -38.53; HRMS (ESI): m/z calcd. for C₂₅H₂₄NO₇F₃S₃+Na⁺: 626.0559 [*M*+Na]⁺; found: 626.0572.

N-(phenylsulfonyl)-N-(2-((trifluoromethyl)thio)cyclohexyl)benzenesulfonamide (13)

Title compound **13** was prepared by the following procedure: In a 2 mL pressurizable reaction tube were meassured $(PhSO_2)_2NSCF_3$ (**1**) (40 mg, 0.1 mmol, 1.0 equiv.) and $Rh_2(OAc)_4$ (**4**) (0.5 mg, 0.001 mmol, 0.01 equiv.)

under ambient conditions. In a dry argon filled glovebox was added a solution of diazo compound **2** (0.12 mmol, 1.2 equiv.) and cyclohexene oxide (**9**) (1.0 mmol, 10 equiv.) in 0.5

mL dry CH₂Cl₂ to the reaction vial. The mixture in the closed reaction vial was stirred for 24 h before being transferred directly on a chromatography column and purified on silica gel (SiO₂; petroleum ether / Et₂O, 3:1) affording **13** as a yellowish solid (12 mg, 24%). ¹H NMR (400 MHz, CDCl₃): δ = 8.26-7.82 (m, broad, 4H), 7.71-7.64 (m, 2H), 7.61-7.53 (m, 4H), 4.24 (td, *J* = 11.5 Hz, 4.1 Hz, 1H), 3.76 (td, *J* = 11.8 Hz, 3.7 Hz, 1H), 2.47-2.39 (m, 1H), 4.93 (qd, *J* = 12.5 Hz, 3.5 Hz 1H), 1.79-1.68 (m, 2H), 1.68-1.60 (m, 1H), 1.60-1.48 (m, 1H), 1.39-1.10 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 144.3 (broad), 141.5 (broad), 138.4 (broad), 134.0 (broad), 130.9 (q, *J*(C,F) = 307.1 Hz), 129.1 (broad), 65.7 (q, *J*(C,F) = 1.0 Hz), 41.7 (q, *J*(C,F) = 1.7 Hz), 37.0 (q, *J*(C,F) = 0.9 Hz), 32.8, 26.4, 25.5; ¹⁹F NMR (377 MHz, CDCl₃): δ = -37.81; HRMS (ESI): m/z calcd. for C₁₉H₂₀NO₄F₃S₃+Na⁺: 502.0399 [*M*+Na]⁺; found: 502.0403, Mp: 156-157 °C.

Attempted cleavage of epoxides

When epoxide **9** was reacted with diazoketone **2a** and **1** in the presence of Rh-catalyst we did not observe formation of the expected oxy-trifluoromethylthiolation product **10** (Figure S1a). Instead we isolated amino-trifluoromethylthiol derivative **13**. A possible explanation is a Rhcatalyzed deoxygenation⁵ of **9** by diazoketone **2a** to give **11** and cyclohexene **12** (Figure S1b). Subsequently, cyclohexene **12** reacted with **1** to give **13**.⁴




Figure S1: Attempted oxy-trifluoromethylthiolation with epoxide 9.

Mechanistical aspects: competitive fluorination vs. trifluoromethylthiolation and proposed catalytic cycle

When a reaction was carried out in the absence of alcohol **3**, amino-trifluoromethylthiolation product **14** did not form (Figure S2a). This clearly shows that the $N(SO_2Ph)_2$ group cannot serve as nucleophile in place of the alkoxy groups. This control reaction shows a clear difference between the reactivity of NFSI and **1**. Using NFSI in place of **1** allows aminofluorination of diazocarbonyl compounds to be performed under similar conditions.^{6, 7} We also have performed a competitive experiment between **1** and NFSI (Figure S2b). This experiment shows that under exactly the same reaction conditions oxy-trifluoromethylthiolation and –fluorination of diazoketones can be performed giving the analogous products **5a** and **15** in a ratio of 1:2.4. This suggests that the mechanisms of the two reactions are very similar and that the fluorine atom transfer is faster than transfer of the SCF₃ group from the same dibenzenesulfonimide carrier.




Figure S2: Control experiment without alcohol **3**, competitive fluorination/ trifluoromethylthiolation under limiting conditions. ^{*a*} Determined by ¹H-NMR-spectroscopy.

A plausible catalytic cycle for the Rh-catalyzed oxy-trifluromethylthiolation is given in Figure S3. The reactions with both dibenzenesulfonimide reagents (1 and NFSI) or fluoro/trifluoromethyl-benziodoxols start with formation of Rh-carbenoid⁸ 16 from 2a and the catalyst 4, which subsequently reacts with an alcohol, such as 3a to give onium ylide 17.⁹⁻¹⁴ The subsequent step is trapping onium ylide 17 by the SCF₃ electrophile. Although the trapping of onium ylids with electrophiles is a well studied and documented process,¹⁴ using F,¹⁵ CF₃ ¹⁵ and SCF₃ (the above study) as electrophiles is a very new direction for this process. A possible oxidative addition of 1 with ylide 17 may result in 18, which undergoes reductive elimination to give product 5a and the regenerated catalyst 4. In the case of using ethers 6-7 instead of alcohols 3 as substrates a similar mechanism can be suggested. It is well known¹⁴ that ethers are also able to form onium ylids (such as 17), which can be trapped by electrophiles. The main difference is that in the onium ylide formed from ethers has an oxygen atom with *two* alkyl groups (instead of an alkyl group and a proton, as in 17).






Figure S3: Plausible mechanism for the rhodium-catalyzed trifluoromethylthiolation reaction of diazo compounds together with alcohols.



¹³C NMR (CDCl₃, 100 MHz). 2-(Benzyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5a)






0


ŚCF₃

¹⁹F NMR (CDCl₃, 377 MHz). 2-(Benzyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5a)





-100 -110 f1 (ppm) 10 -120 0 -10 -20 -30 -40 -50 -60 -70 -80 -90 -130 -140 -150 -160 -170 -180 -190 -200 -210 S19


¹H NMR (CDCl₃, 400 MHz). 2-(Naphthalen-2-ylmethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5b**)


















68---









¹H NMR (CDCl₃, 400 MHz). 2-((2-Bromobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5c**)







2,28



¹³C NMR (CDCl₃, 100 MHz). 2-((2-Bromobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5c)





¹⁹F NMR (CDCl₃, 377 MHz). 2-((2-Bromobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5c**)




-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65 f1 (pp	-70 pm)	-75	-80	-85	-90	-95	-100	-105	-110	-115	-120	-125

¹H NMR (CDCl₃, 400 MHz). 2-((4-Nitrobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5d**)










S26

¹³C NMR (CDCl₃, 100 MHz). 2-((4-Nitrobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5d**)






¹⁹F NMR (CDCl₃, 377 MHz). 2-((4-Nitrobenzyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5d**)




-25 -30 -35 -40 -45 -50 -55 -60 -65 -70 -75 -80 -85 -90 -95 -100 -105 -110 -115 -120 -125 -130 -135																
f1 (ppm)	-130	-135														




S29


¹³C NMR (CDCl₃, 100 MHz). 2-(Benzo[*d*][1,3]dioxol-5-ylmethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5e**)





¹⁹F NMR (CDCl₃, 377 MHz). 2-(Benzo[*d*][1,3]dioxol-5-ylmethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5e**)

---38.46













¹⁹F NMR (CDCl₃, 377 MHz). 2-(Hexyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5f)

8080----












¹³C NMR (CDCl₃, 100 MHz). 2-(Cycloheptyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5g)

S36


¹⁹F NMR (CDCl₃, 377 MHz). 2-(Cycloheptyloxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5g)










¹³C NMR (CDCl₃, 100 MHz). 2-(((1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5h**)








¹⁹F NMR (CDCl₃, 377 MHz). 2-(((1*R*,2*S*,5*R*)-2-Isopropyl-5-methylcyclohexyl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (**5h**)













f1 (ppm) ¹⁹F NMR (CDCl₃, 377 MHz). 2-((3-Methylbut-2-en-1-yl)oxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5i)

---38.62






0 **,**0. 4.481 4.481 4.44 -24 SCF3 1.00-1 3.00-1.99.1 2.00 Å 1.61 1.02-1 4.5 f1 (ppm) 8.0 7.5 7.0 6.5 5.5 5.0 4.0 3.5 3.0 2.5 2.0 1.5 9.0 8.5 6.0 1.0 0.5 0.0


Br


¹H NMR (CDCl₃, 400 MHz). 2-((4-Bromobenzyl)oxy)-1-(*p*-tolyl)-2-((trifluoromethyl)thio)ethan-1-one (5j)





¹⁹F NMR (CDCl₃, 377 MHz). 2-((4-Bromobenzyl)oxy)-1-(*p*-tolyl)-2-((trifluoromethyl)thio)ethan-1-one (5j)

---38.60












¹³ C NMR (C	DCl ₃ , 100 MHz). 2-(Benzyloxy)-1-cyclopentyl-2-((tr	ifluorome	ethyl)thio)ethan-1-on	e (5k)
26.402	2 A A A A A A A A A A A A A A A A A A A	888 858 858 858 858 858 858 858 858 858	202	01.79	22.22 22.22 22.22
- T	SYV	- VP	1	1	V V







¹⁹F NMR (CDCl₃, 377 MHz). 2-(Benzyloxy)-1-cyclopentyl-2-((trifluoromethyl)thio)ethan-1-one (**5k**)




10 0 -10 -20 -30	-40 -50 -60 -70 -80 -90	150 -160 -170 -180 -190 -200 -210








¹⁹F NMR (CDCl₃, 377 MHz). 1-(Benzyloxy)-1-((trifluoromethyl)thio)undecan-2-one (5l)

----37.35













¹⁹F NMR (CDCl₃, 377 MHz). 1-(Hexyloxy)-1-((trifluoromethyl)thio)undecan-2-one (5m)


---37.64















---35.33












¹⁹F NMR (CDCl₃, 377 MHz). Ethyl 2-(benzyloxy)-2-((trifluoromethyl)thio)acetate (**50**)





	<u>ــــــــــــــــــــــــــــــــــــ</u>
10 0 -10 -20 -30	-40 -50 -60 -70 -80 -90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -200 -210 f1 (ppm)







¹⁹F NMR (CDCl₃, 377 MHz). Methyl 2-(benzyloxy)-2-phenyl-2-((trifluoromethyl)thio)acetate (**5p**)











¹³C NMR (CDCl₃, 100 MHz). 2-Methoxy-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5q)

131.86 129.55 129.09 125.74

134.92 134.75 133.02






88.82 88.30 88.79 88.77 ----54.58

¹⁹F NMR (CDCl₃, 377 MHz). 2-Methoxy-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5q)





																						· · · ·
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100	-110	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210
											f1 (ppm)										

¹H NMR (CDCl₃, 400 MHz). 1-(4-Bromophenyl)-2-methoxy-2-((trifluoromethyl)thio)ethan-1-one (**5r**)




¹³C NMR (CDCl₃, 100 MHz). 1-(4-Bromophenyl)-2-methoxy-2-((trifluoromethyl)thio)ethan-1-one (**5**r)







----38.65



 1		1	· · ·			· · · ·	1	· · ·					· · ·	· · ·	' '	· · ·	· · ·		· · ·	· · ·	· · ·	
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90			-120	-130	-140	-150	-160	-170	-180	-190	-200	-210
											f1 (ppm)										




¹³C NMR (CDCl₃, 100 MHz). 2-(2-(2-Methoxyethoxy)ethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5s)




0


¹⁹F NMR (CDCl₃, 377 MHz). 2-(2-(2-Methoxyethoxy)-1-phenyl-2-((trifluoromethyl)thio)ethan-1-one (5s)

----38.55






¹H NMR (CDCl₃, 400 MHz). *N*-(4-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (**8a**)



S74

¹³C NMR (CDCl₃, 100 MHz). *N*-(4-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8a)




¹⁹F NMR (CDCl₃, 377 MHz). N-(4-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)butyl)-N-(phenylsulfonyl)benzenesulfonamide (8a)

----38.54

N(SO₂Ph)₂ ∫ SCF₃

· · · ·	1					' '	· · ·	· · ·				· · ·		' '	' '							· · · ·
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100 f1 (ppm		-120	-130	-140	-150	-160	-170	-180	-190	-200	-210







N(SO₂Ph)₂


2


|\ SCF₃




¹⁹F NMR (CDCl₃, 377 MHz). *N*-(4-(4-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)butoxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (**8b**)















¹⁹F NMR (CDCl₃, 377 MHz). *N*-(4-((2-oxo-1-((trifluoromethyl)thio)undecyl)oxy)butyl)-*N*-(phenylsulfonyl)benzenesulfonamide (8c)


----37.61

 C_8H_{17} V $N(SO_2Ph)_2$ SCF₃

10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100 f1 (ppm	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210




¹³C NMR (CDCl₃, 100 MHz). Ethyl 2-(4-(*N*-(phenylsulfonyl)phenylsulfonamido)butoxy)-2-((trifluoromethyl)thio)acetate (8d)




¹⁹F NMR (CDCl₃, 377 MHz). Ethyl 2-(4-(*N*-(phenylsulfonyl)phenylsulfonamido)butoxy)-2-((trifluoromethyl)thio)acetate (**8d**)

-----38.57




	1																					
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100 f1 (ppm	-110)	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210

¹H NMR (CDCl₃, 400 MHz). N-(2-((2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)methyl)benzyl)-N-(phenylsulfonyl)benzenesulfonamide (**8e**)








¹³C NMR (CDCl₃, 100 MHz). N-(2-((2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)methyl)benzyl)-N-(phenylsulfonyl)benzenesulfonamide (**8e**)


`N[´]SO₂Ph


SO₂Ph


ŚCF₃



¹⁹F NMR (CDCl₃, 377 MHz). *N*-(2-((2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)methyl)benzyl)-*N*-(phenylsulfonyl)benzenesulfonamide (**8e**)








S89




N(SO₂Ph)₂


SCF3



¹⁹F NMR (CDCl₃, 377 MHz). N-(2-(2-(2-oxo-2-phenyl-1-((trifluoromethyl)thio)ethoxy)ethoxy)ethyl)-N-(phenylsulfonyl)benzenesulfonamide (**8f**)




	1														' '							
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100 f1 (ppm)	-110)	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210



S92

¹³C NMR (CDCl₃, 100 MHz). *N*-(phenylsulfonyl)-*N*-(2-((trifluoromethyl)thio)cyclohexyl)benzenesulfonamide (**13**)



¹⁹F NMR (CDCl₃, 377 MHz). *N*-(phenylsulfonyl)-*N*-(2-((trifluoromethyl)thio)cyclohexyl)benzenesulfonamide (**13**)

----37.81

 SCF_3 N(SO₂Ph)₂

	1											 									
10	0	-10	-20	-30	-40	-50	-60	-70	-80	-90	-100 f1 (ppm	-120	-130	-140	-150	-160	-170	-180	-190	-200	-210

References:

- 1. Martin, L. J.; Marzinzik, A. L.; Ley, S. V.; Baxendale, I. R., *Org. Lett.* **2011**, *13*, 320-323.
- 2. Das, A.; Wang, D.; Belhomme, M.-C.; Szabó, K. J., Org. Lett. 2015, 17, 4754-4757.
- Lall, M. S.; Ramtohul, Y. K.; James, M. N. G.; Vederas, J. C., J. Org. Chem. 2002, 67, 1536-1547.
- Zhang, P.; Li, M.; Xue, X.-S.; Xu, C.; Zhao, Q.; Liu, Y.; Wang, H.; Guo, Y.; Lu, L.; Shen, Q., J. Org. Chem. 2016, 81, 7486-7509.
- 5. Martin, M. G.; Ganem, B., *Tetrahedron Lett.* **1984**, *25*, 251-254.
- 6. Chen, G.; Song, J.; Yu, Y.; Luo, X.; Li, C.; Huang, X., *Chem. Sci.* **2016**, *7*, 1786-1790.
- 7. Huang, J.; Li, L.; Chen, H.; Xiao, T.; He, Y.; Zhou, L., Org. Chem. Front. 2017, 4, 529-533.
- 8. Werlé, C.; Goddard, R.; Philipps, P.; Farès, C.; Fürstner, A., J. Am. Chem. Soc. 2016, 138, 3797-3805.
- 9. Doyle, M. P., Acc. Chem. Res. 1986, 19, 348-356.
- 10. Doyle, M. P.; Duffy, R.; Ratnikov, M.; Zhou, L., *Chem. Rev.* **2010**, *110*, 704-724.
- 11. Xiao, Q.; Zhang, Y.; Wang, J., Acc. Chem. Res. 2013, 46, 236-247.
- 12. Xia, Y.; Zhang, Y.; Wang, J., ACS Catal. 2013, 3, 2586-2598.
- 13. Padwa, A.; Hornbuckle, S. F., *Chem. Rev.* **1991**, *91*, 263-309.
- 14. Guo, X.; Hu, W., Acc. Chem. Res. 2013, 46, 2427-2440.
- 15. Yuan, W.; Eriksson, L.; Szabó, K. J., Angew. Chem. Int. Ed. 2016, 55, 8410-8415.